ICPT

Ocaliva

Adult nonalcoholic steatohepatitis (NASH)

Report out on post-CRL FDA meeting

Exp Date

November 06, 2020 (Est)

Amp Volatility Score

46%

Catalyst Info & Data Links

TITLE: Ocaliva in Adult nonalcoholic steatohepatitis (NASH) - Post-CRL FDA meeting

  • ClinicalTrial.gov NCT02548351: Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE)


WHAT IS THE CATALYST EVENT?

  • Post-CRL FDA meeting


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • November 06, 2020 (Est)


PRIOR DATA/EVENTS


PRESS RELEASE

COMPETITORS

  • Cenicriviroc by Allergan

  • Cotadutide by AstraZeneca

  • Elafibranor by Genfit

  • Resmetirom by Madrigal Pharmaceuticals

  • Selonsertib, firsocostat and cilofexor by Gilead

  • Tropifexor and licogliflozin by Novartis

MARKET

  • ~19 million NASH patients

  • ~16 million  patients with fibrosis due to NASH

  • ~1.5M under Hep/GI care

  • Source: J.P. Morgan 38th Annual Healthcare Conference (slide 13) 

MECHANISM OF ACTION/RATIONALE

  • Obeticholic acid is an agonist for FXR, a nuclear receptor expressed in the liver and intestine. FXR is a key regulator of bile acid, inflammatory, fibrotic, and metabolic pathways. FXR activation decreases the intracellular hepatocyte concentrations of bile acids by suppressing de novo synthesis from cholesterol as well as by increased transport of bile acids out of the hepatocytes. These mechanisms limit the overall size of the circulating bile acid pool while promoting choleresis, thus reducing hepatic exposure to bile acids. (page 10

Updated by HC

ICPT, Ocaliva, NASH

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

ICPT - Q2 2020 Ocaliva Net Sal...

#ICPT reported Q2 2020 Financial Results. Summary: Worldwide Ocaliva net sales of $77.2 million in the second quarter 2020, representing 17% growth over the prior year quarter  Intercept issues 2...

Trilaciclib NDA Filing (GTHX)...

We are fans of GTHX and hope things go well. But we are worried if NDA for Trilaciclib in NSCLC is accepted and accelerated date is set, that expedited PDUFA is too rushed for FDA during a pandemic. S...

ICPT CRL for Ocaliva
...

Intercept Pharmaceuticals, Inc. received a Complete Response Letter from the U.S. FDA for the NDA for Ocaliva which is used for Adult nonalcoholic steatohepatitis (NASH). The FDA stated that the CRL w...

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon